The utility of PD-L1 tumor status in predicting response to nivolumab and nivolumab plus ipilimumab combined therapy was analyzed in tumor pre-treatment biopsies from melanoma patients enrolled in the CheckMate 067 trial. The gene discussed is CD274; the disease is neoplasm.